Mika Grasso was named Chief Executive Officer of BioRestorative Therapies, Inc. As of November 6, 2026, BioRestorative Therapies, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 12, 2026 to September 11, 2026, naming 5 appointments and 1 departure (Form 8-K, September 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like BioRestorative Therapies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-09-11
- · In / out: In · Person: Mika Grasso · Role: Chief Executive Officer · 8-K, 2026-09-02
- · In / out: Out · Person: David Rosa · Role: Director · 8-K, 2026-07-16
- · In / out: In · Person: Mika Grasso · Role: Director · 8-K, 2026-06-12
BioRestorative Therapies, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-12 to 2026-09-11. They name 5 people, with 5 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as BioRestorative Therapies, Inc. files it.
Also on the record for BioRestorative Therapies, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 3, 2026 | Stake report, Schedule 13G/A, by Alta Partners LLC | 4.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Auctus Fund, LLC | 9.9% of the class | 5%+ stakes | Source |
| February 23, 2026 | Stake report, Schedule 13G/A, by Morrison Todd Hale | — | 5%+ stakes | Source |
| February 18, 2026 | Stake report, Schedule 13G, by Mitchell P. Kopin | 4.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Auctus Fund, LLC | 9.9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G, by Alta Partners LLC | 7.7% of the class | 5%+ stakes | Source |
| December 19, 2025 | Stake report, Schedule 13G/A, by Morrison Todd Hale | 7.7% of the class | 5%+ stakes | Source |
| October 9, 2025 | Form D, private offering | $1.40M sold | Form D page | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Auctus Fund, LLC | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs BioRestorative Therapies, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on BioRestorative Therapies, Inc. and the records around it.
BioRestorative Therapies, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- Alta Partners LLC also filed stake reports on 26 other companies: Robin Energy Ltd. (Oct 2026), Huachen AI Parking Management Technology Holding Co., Ltd (Oct 2026), C3is Inc. (Oct 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
Watch BioRestorative Therapies, Inc.
Get an email when BioRestorative Therapies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BioRestorative Therapies, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BioRestorative Therapies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioRestorative Therapies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-11 | Reported | not named in the filing | 8-K, 2026-09-11 | ||
| 2026-09-02 | In | Chief Executive Officer | 8-K, 2026-09-02 | ||
| 2026-09-02 | In | Chairman of the Board | 8-K, 2026-09-02 | ||
| 2026-07-16 | Out | Director | 8-K, 2026-07-16 | ||
| 2026-07-16 | In | Chief Executive Officer | 2026-07-13 | 8-K, 2026-07-16 | |
| 2026-07-16 | In | Director | 8-K, 2026-07-16 | ||
| 2026-06-12 | In | Director | 8-K, 2026-06-12 |
Who leads BioRestorative Therapies, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chairman of the Board: Steven Brown, appointed (filed 2026-09-02).
- Chief Executive Officer: Mika Grasso, appointed (filed 2026-09-02).
- Director: David Rosa, departure reported (filed 2026-07-16). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on BioRestorative Therapies, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at BioRestorative Therapies, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at BioRestorative Therapies, Inc.Every change, in the filing's words
Reported
On September 4, 2026, BioRestorative Therapies, Inc. (the " Company ") received a notice of resignation from Mr. Silva from his employment with the Company, including as the Company's Vice President of Research and Development, and from each other position (if any) he held as an officer of the Company, effective immediately.
- If the resignation were ultimately determined to constitute a resignation for "Good Reason" within the meaning of the Employment Agreement, and the Employment Agreement was held to be valid and binding on the Company, Mr. Silva would assert entitlement to cash severance payments of approximately $1.29 million, acceleration of outstanding equity awards, and continuation of certain benefits.
- The Board has acknowledged the resignation for corporate-records and disclosure purposes, effective as of the date set forth in the notice.
- The Board has not accepted, and does not concede, the validity or effect of the Employment Agreement or the characterizations set forth in the resignation notice, including the assertions that a "Change in Control" occurred or that the resignation constitutes a resignation for "Good Reason," and the Company has reserved all of its rights, claims and defenses with respect thereto.
Appointed: Mika Grasso, Chief Executive Officer
On August 26, 2026, the Board appointed Mika Grasso as the Company's Interim Chief Executive Officer, effective immediately.
Appointed: Steven Brown, Chairman of the Board
On September 1, 2026, the Board also appointed Mr. Brown as Chairman of the Board.
- Transition of Katharyn Field On August 26, 2026, Katharyn Field advised the Board that she wished to step aside as the Company's Interim Chief Executive Officer and Chief Financial Officer, and the Board accepted her request effective as of that date.
- Ms. Field also ceased to serve as the Company's interim Chief Financial Officer and Treasurer effective August 27, 2026, upon the appointment of her successor as described below, and as Secretary effective August 26, 2026, and resigned as a member of the Board effective August 31, 2026.
- Ms. Field's transition and resignation were not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- In connection with her transition, the Company entered into a consulting agreement, dated as of August 27, 2026 (the "Field Consulting Agreement"), with EEAK Consulting LLC, a Wyoming limited liability company of which Ms. Field is a partner ("EEAK"), pursuant to which Ms. Field will provide advisory and transition services to the Company.
- Under the Field Consulting Agreement, the Company will pay EEAK a monthly fee of $10,000 (plus applicable taxes), and EEAK is eligible to participate in incentive and equity-based compensation plans made available to the Company's management, subject to the terms of the applicable plan documents.
Departing: David Rosa, Director
On July 11, 2026, David Rosa resigned as a director of the Company and from each committee of the Board of Directors of the Company (the "Board") on which he served, including the Compensation Committee, effective immediately.
Appointed: Katharyn Field, Chief Executive Officer, effective 2026-07-13
Effective July 13, 2026, the Board appointed Katharyn Field, a director of the Company, as an officer of the Company and, by unanimous written consent, the Board confirmed Ms. Field's appointment as Chief Executive Officer and President of the Company and, on an interim basis pending completion of the Board's search for a permanent Chief Financial Officer, as interim Chief Financial Officer, Treasurer and Secretary of the Company.
Appointed: Esha Randhawa, Director
On July 13, 2026, the Board elected Esha Randhawa as a Class II director of the Company, with a term expiring at the Company's 2028 annual meeting of stockholders, filling the vacancy created by Mr. Rosa's resignation, and, on July 14, 2026, the Board elected Steven Brown as a Class III director of the Company, with a term expiring at the Company's 2026 annual meeting of stockholders, filling the vacancy created by Mr. Alstodt's cessation of service as a director.
- As executed on May 27, 2026 and June 10, 2026, Section 9 of each Employment Agreement provided that, upon a "Change in Control" of the type described in clause (i) (acquisition of more than 50% of voting power) or clause (ii) (change in the majority of the incumbent Board) of the definition thereof, the executive would be entitled to receive the cash severance amount provided for in the Employment Agreement, and to accelerated vesting of all outstanding equity awards, whether or not the executive's employment terminated.
- The Employment Agreement Amendments revised Section 9 of each Employment Agreement so that such payment and vesting provisions apply only upon a Change in Control of the type described in clause (iii) of the definition (in substance, a reorganization, merger or consolidation in which the Company's stockholders cease to hold a majority of the voting power, or a sale of all or substantially all of the Company's assets).
- The Employment Agreement Amendments did not amend the definition of "Change in Control" or the definition of "Good Reason" in the Employment Agreements.
- Mr. Rosa's resignation notice did not state any reason for his resignation, and his resignation was not, to the Company's knowledge, the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Appointed: Mika Grasso, Director
(d) On June 12, 2026, pursuant to the Revolving Loan Agreement, the remaining members of the Company's Board of Directors (the "Board") appointed Mika Grasso, Katharyn Field and Jatinder Dhaliwal (collectively, the "New Directors"), designees of the Lender, as directors of the Company.
- hereof with regard to the resignation of certain directors of the Company pursuant to the Revolving Loan Agreement and the appointment of certain new directors designated by the Lender.
- (b) Effective June 11, 2026, pursuant to the Revolving Loan Agreement, Francisco Silva, Nickolay Kukekov and Patrick F. Williams resigned as directors of the Company.
- Mr. Grasso was appointed as a Class II director whose term will expire at the Company's annual meeting of stockholders in 2028.
- He has been appointed as Chair of the Audit Committee and a member of the Compensation Committee.
- Ms. Field was appointed as a Class I director whose term will expire at the Company's annual meeting of stockholders in 2027.
- She has been appointed as Chair of the Nominating Committee.
- Mr. Dhaliwal was appointed as a Class III director whose term will expire at the Company's annual meeting of stockholders in 2026.
- He has been appointed a member of the Audit Committee, Compensation Committee and Nominating Committee.
Tools for this story
Each opens in a new tab, filled in for BioRestorative Therapies, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.